Cargando…
Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin
BACKGROUND: Continuous infusion of doxorubicin or dexrazoxane pre-treatment prior to bolus doxorubicin are proven strategies to protect against doxorubicin-induced cardiotoxicity. Recently, global longitudinal peak systolic strain (GLS) measured with speckle tracking echocardiography (STE) and high-...
Autores principales: | Li, Jieli, Chang, Hui-Ming, Banchs, Jose, Araujo, Dejka M., Hassan, Saamir A., Wagar, Elizabeth A., Yeh, Edward T. H., Meng, Qing H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048030/ https://www.ncbi.nlm.nih.gov/pubmed/32154027 http://dx.doi.org/10.1186/s40959-019-0056-3 |
Ejemplares similares
-
Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma
por: Narayan, Hari K, et al.
Publicado: (2019) -
Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion
por: Quintana, Raymundo A., et al.
Publicado: (2017) -
Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study
por: QuanJun, Yang, et al.
Publicado: (2017) -
Cisplatin/dexrazoxane/doxorubicin: Neutropenia and thrombocytopenia: case report
Publicado: (2020) -
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
por: Kopp, Lisa M., et al.
Publicado: (2019)